In this podcast, Contributing Editor Dr. Irene Ghobrial has a conversation with Dr. Shaji Kumar. They discuss Dr. Ghobrial’s Year’s Best article from the January/February 2021 issue of The Hematologist, titled, "The BELLINI Study and the Dawn of Precision Medicine in Multiple Myeloma." They discuss a randomized, double-blinded, phase III trial testing the combination of venetoclax or placebo with bortezomib and dexamethasone in relapsed or refractory multiple myeloma. You can access her Year’s Best article online at https://ashpublications.org/thehematologist/article/474709/The-BELLINI-Study-and-the-Dawn-of-Precision.

Conflicts of Interest: Dr. Kumar has received research funding for clinical trials to the institution from Abbvie, Amgen, BMS, Carsgen, Janssen, KITE, Merck, Medimmune, Novartis, Roche-Genentech, Takeda, and Tenebio, and has consulted or participated in advisory boards (with no personal payments) for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, and (with personal payment) Oncopeptides, Beigene. Dr. Ghobrial has consulted for GSK (and Advisory Board participation), Sanofi, Janssen, Takeda, Karyopharm, AbbVie, GNS (Ad. Board participation), Cellectar, Medscape, Genentech, Adaptive, BMS, Aptitude (Ad. Board participation), and Curio Science.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/